GlassScriptPhysician profile
Iris N Bosse
NPI 1073130688
$5,018.26
in general payments reported to CMS, 2019-2025
21 companies · $769 in 2025
The $769 reported for 2025 was more than what 82% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,557 · 2022: $1,265 · 2023: $755 · 2024: $673 · 2025: $769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,097 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,097.22 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,079.86 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,120.95 | 2021-2023 | Trulance, Plenvu, Xifaxan |
| Janssen Biotech, INC. | $316.95 | 2023-2025 | Tremfya, Stelara, Simponi |
| Regeneron Healthcare Solutions, INC. | $233.09 | 2022-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $175.45 | 2021-2024 | Entyvio |
| Vivus LLC | $172.70 | 2021-2022 | |
| Evoke Pharma, INC. | $161.71 | 2021-2023 | Gimoti |
| Nestle Healthcare Nutrition INC. | $159.22 | 2021-2022 | |
| Ardelyx, INC. | $125.78 | 2023-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $92.77 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $79.47 | 2024-2025 | Resmetirom, Rezdiffra |
| Braintree Laboratories, INC. | $46.36 | 2022-2024 | Sutab, Suflave |
| Gilead Sciences, INC. | $42.10 | 2021-2022 | |
| Genzyme Corporation | $38.95 | 2023-2024 | |
| Boston Scientific Corporation | $38.22 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $32.99 | 2024 | Terlivaz |
| Redhill Biopharma INC. | $22.92 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $21.82 | 2025 | Iqirvo |
| Exact Sciences Corporation | $21.52 | 2023 | Cologuard Collection Kit |
| Lilly USA, LLC | $18.01 | 2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $17.42 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iris Bosse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.